Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity

• Main Authors: Salinee Jantrapirom, Wutigri Nimlamool, Nipon Chattipakorn, Siriporn Chattipakorn, Piya Temviriyanukul, Woorawee Inthachat, Piyarat Govitrapong, Saranyapin Potikanond
• 格式: 雜誌
• 出版: 2020
• 主題: Biochemistry, Genetics and Molecular Biology; Chemical Engineering; Chemistry; Computer Science
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85080984217&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/68238

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Neuronal insulin resistance is a significant feature of Alzheimer’s disease (AD). Accumulated evidence has revealed the possible neuroprotective mechanisms of antidiabetic drugs in AD. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog and...